CA2634784A1 - Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations - Google Patents

Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations Download PDF

Info

Publication number
CA2634784A1
CA2634784A1 CA002634784A CA2634784A CA2634784A1 CA 2634784 A1 CA2634784 A1 CA 2634784A1 CA 002634784 A CA002634784 A CA 002634784A CA 2634784 A CA2634784 A CA 2634784A CA 2634784 A1 CA2634784 A1 CA 2634784A1
Authority
CA
Canada
Prior art keywords
glp
seq
mimetibody
cell
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002634784A
Other languages
English (en)
Inventor
Karyn T. O'neil
Kristen Picha
Vedrana Stojanovic-Susulic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor, Inc.
Karyn T. O'neil
Kristen Picha
Vedrana Stojanovic-Susulic
Centocor Ortho Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc., Karyn T. O'neil, Kristen Picha, Vedrana Stojanovic-Susulic, Centocor Ortho Biotech Inc. filed Critical Centocor, Inc.
Publication of CA2634784A1 publication Critical patent/CA2634784A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
CA002634784A 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations Abandoned CA2634784A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75282605P 2005-12-22 2005-12-22
US60/752,826 2005-12-22
PCT/US2006/062223 WO2007076319A2 (fr) 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations

Publications (1)

Publication Number Publication Date
CA2634784A1 true CA2634784A1 (fr) 2007-07-05

Family

ID=38218787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002634784A Abandoned CA2634784A1 (fr) 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations

Country Status (4)

Country Link
EP (1) EP1968645A4 (fr)
JP (1) JP2009526750A (fr)
CA (1) CA2634784A1 (fr)
WO (1) WO2007076319A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
WO2009059278A1 (fr) * 2007-11-02 2009-05-07 Centocor, Inc. Produits d'assemblage semi-synthétiques obtenus par fusion de peptide glp-1/fc, procédés et utilisations
WO2009099961A2 (fr) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molécules modifiées du type anticorps, à domaine constant
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation
JP2023528921A (ja) 2020-06-03 2023-07-06 ケブンハウンス、ウニバーシテート Ｇｌｐ１ｒアゴニスト・ｎｍｄａｒアンタゴニストコンジュゲート

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011425A (es) * 2004-03-31 2007-03-12 Johnson & Johnson Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.

Also Published As

Publication number Publication date
EP1968645A4 (fr) 2009-11-04
WO2007076319A3 (fr) 2008-10-30
WO2007076319A2 (fr) 2007-07-05
JP2009526750A (ja) 2009-07-23
EP1968645A2 (fr) 2008-09-17

Similar Documents

Publication Publication Date Title
US7833531B2 (en) Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
US8071103B2 (en) Pharmaceutical composition comprising a human GLP-1 mimetibody
US20070135338A1 (en) Human GLP-1 mimetibodies, compositions, methods and uses
US20070128193A1 (en) GLP-1 agonists, compositions, methods and uses
EP1675579A2 (fr) Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes
CA2634784A1 (fr) Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations
US20120082669A1 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia
AU2007303527A1 (en) Human EPO receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions
CA2603359A1 (fr) Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20121218